The United States has a patent on treating cancer with isolated forms of phytocannabinoids
According to a 2013 patent application the United States has an invention related to the use of phytocannabinoids, either in an isolated form or in the form of a botanical drug substance (BDS), as a prophylactic or in the therapeutic treatment of cancer.
In 1986 THC was licensed as an anti-emetic drug in cancer patients receiving chemotherapy
In 1986, delta-9-tetrahydrocannabinol (THC), the main effective constituent of cannabis, was licensed as an anti-emetic drug in cancer patients receiving chemotherapy. In addition, in clinical studies, THC has shown significant stimulation of appetite and an increase in body weight in HIV-positive and cancer patients.